Telesis Bio (NASDAQ: TBIO) Stock Hits 1 Month High: Now What?
On Thursday, there were a number of companies that had seen their stocks clock significant gains, and one such company was Telesis Bio (NASDAQ: TBIO), which saw its stock clock gains of 72% for the day.
Telesis Bio and Beckman Coulter Life Sciences Collaborate to Revolutionize DNA and mRNA Synthesis
On September 25, it emerged that Telesis Bio and global laboratory innovation and automation leader Beckman Coulter Life Sciences had gone into a partnership. Through the partnership, the two parties would aim to create scalable and efficient offerings, which would help in the sustainable and fast on-premise development of DNA. Through this partnership, the company’s Gibson SOLA enzymatic reagent platform would run on Beckman Coulter’s automation.
The integration would help in the production of reliable and highly scalable high-fidelity DNA production at a rapid pace. Additionally, such a program would also provide researchers with the opportunity of producing higher productivity in a range of discovery-based applications. It would also provide the wider market with an open solution and hence allow the integration of constructs from other providers that may be compatible with Gibson SOLA from Telesis Bio. The partnership could be seen as a major step in making a significant leap in the field of synthetic biology. Investors could do well to keep an eye on Telesis Bio today.
Key Comment
Eric Esser, CEO of Telesis Bio, commented on the collaboration: “This partnership marks a significant milestone in advancing synthetic biology. By integrating Gibson SOLA’s high-fidelity, scalable, and non-toxic DNA synthesis capabilities with Beckman Coulter Life Sciences automation expertise, we are setting a new standard for on-premises biofoundries. This collaboration empowers researchers to greatly improve productivity through faster, more reliable, and innovative solutions, driving forward the next generation of therapeutic and diagnostic advancements.”
